This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.
The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-08; most recent amendment 2026-02-12.
Status change: Recruiting → Active, Not Recruiting2025-09-08